Phase 2 N=31 NeuroCognition After Carotid Recanalization
Cognition Disorder · Stroke · Occlusion Carotid
Primary: Change in Montreal Cognitive Assessment (MoCA) Score — 0.56; 1.38; -0.75; 0.50 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=42 Enhancing the Effects of Adolescent Alcohol Treatment With Atomoxetine
Alcohol Use Disorder
Primary: Completion Rates — 17; 18 Participants
Phase 2 N=70 Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel)
MacTel (Macular Telangiectasia) Type 2
Primary: Ellipsoid Zone (Area of IS/OS Loss) - Cohort 1 — 0.697; 0.629; 1.37; 1.137 mm2
Phase 2 N=55 A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)
Squamous Cell Carcinoma of Head and Neck
Primary: Best Percentage Change in Tumour Size — -7.88; -12.93 Percentage change from baseline — p=0.7008
Phase 2 N=168 Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)
Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease
Primary: Histological Improvement in Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS) Without Worsening of Fibrosis (by NASH Clinical Research Network [CRN] Fibrosis…
Phase 2 N=71 Imaging Tau in Alzheimer's Disease and Normal Aging
Alzheimer Disease
Primary: 18F-MK-6240 Binding — 1.41; 2.30 SUVr
Phase 2 N=226 Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine (GSK3878858A) When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)
Infections, Soft Tissue
Primary: Dose-escalation Safety lead-in: Number of Participants With Any and Grade 3 Solicited Administration Site Adverse Events (AEs) After Each Vaccination — 2; 3; 5; 5…
Phase 2 N=105 A Phase 2 Study to Learn About a Monovalent Pneumococcal Conjugate Candidate in Healthy Toddlers
Healthy Participants
Primary: Percentage of Participants With Local Reactions Within 7 Days After Dose 1 — 17.3; 15.1; 17.3; 9.4 Percentage of participants
Phase 2 N=40 Neuronal Correlates of Neurexan® Action in Mildly to Moderately Stressed Probands
Acute Stress Reaction
Primary: Functional Magnetic Resonance Imaging (fMRI) Task Data: BOLD Activation Changes Within Amygdala During Negative Faces in the Hariri Face Matching Task Between Placebo…
Phase 2 N=27 Bevonescein to Highlight Nerves in Patients Undergoing Head & Neck Surgery
Parotid Neoplasm · Thyroid Neoplasms · Head and Neck Neoplasms
Primary: Safety - The Number of Patients With ALM-488 Related Adverse Events — 0; 0; 0; 0 Participants
Phase 2 N=128 A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)
NASH - Nonalcoholic Steatohepatitis
Primary: Effect of Efruxifermin (EFX) vs Placebo on Fibrosis Regression in Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)-Associated Stage 2 or 3…
Phase 2 N=24 Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis
Multiple Sclerosis
Primary: Change From Baseline in Physical Health Composite Score - Multiple Sclerosis Quality of Life (MSQOL) 54 Instrument — 53.85; 44.07; 8.21; 7.03 score on a scale (100…
Phase 2 N=18 Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
Primary: Safety of Intramuscular Injections of Engensis in Participants With Amyotrophic Lateral Sclerosis Compared to Placebo — 4; 3; 3; 1 Participants
Phase 2 N=34 ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure
Type 2 Diabetes Mellitus · Heart Failure
Primary: Fractional Excretion of Lithium (FELi) — 0.3; -2.3; 0.8; -4.9 percentage of filtered lithium excreted — p=0.36
Phase 2 N=10 Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant
Antibody-mediated Rejection · Kidney Transplant; Complications · Transplant Glomerulopathy
Primary: Number of Participants With Donor Specific Antibody (DSA) Elimination or Reduction Based on Luminex HLA Testing — 7 Participants